Healthcare experts gathered at the Patient-Centered Oncology Care® meeting to discuss the far-reaching implications of the Inflation Reduction Act (IRA) on cancer care innovation, drug development timelines, and patient access to treatments.
Impact on Drug Development Strategy
The IRA's implementation is fundamentally altering pharmaceutical companies' approach to drug development and launches. Derek Asay, senior vice president at Lilly USA, emphasized that the law effectively halves the value of small molecule drugs by limiting their exclusivity to 9 years before price negotiations begin, compared to 13 years for biologics.
"I think what we'll see is you're really trying to truncate that timeline, of really putting those indications close together," Asay explained. This shift complicates the traditional development pathway of starting with later-line treatments before expanding to earlier therapy lines.
Bruce Wilson, vice president at AstraZeneca, highlighted a concerning trend: companies may delay launching drugs for smaller patient populations to protect their pricing potential for larger indications. "Now, instead of launching in a small population [and] helping those patients until that bigger indication comes, now I have to hold [the drug] for the larger indication," Wilson noted.
Patient Affordability Improvements
A significant bright spot in the IRA is its benefit design changes taking effect January 1. The new structure eliminates the Medicare donut hole, implements a $2,000 out-of-pocket cost cap, and introduces cost "smoothing" throughout the year. Asay characterized these changes as "really a game changer for patients and affordability" in oncology care.
Formulary Management and Care Models
The implementation of Medicare fair price (MFP) negotiation raises questions about formulary positioning. While negotiated drugs must be included on formularies, their preferred status isn't guaranteed, potentially affecting treatment access and decision-making.
Dr. Zahra Mahmoudjafari from the University of Kansas Cancer Center emphasized the importance of balanced formulary management, noting that providers sometimes favor newer treatments even when they might not be the optimal choice for patients.
Drug Shortage Crisis
The discussion highlighted ongoing concerns about drug shortages in oncology. Wilson attributed part of the problem to aggressive cost reduction in the generic market, resulting in limited manufacturing facilities for critical medications.
Dr. Mahmoudjafari described the devastating impact of these shortages: "I cannot stress, the ramifications of a drug shortage when you are having to have really difficult, ethical conversations with your multidisciplinary care team as to who gets treatment, who does not."
Future of Value-Based Care
Sam Stolpe of Johnson & Johnson Innovative Medicine expressed optimism about evolving definitions of value in cancer care. He advocated for recognizing that "high-cost, high-value therapies are delivering a tremendous amount of value," suggesting a needed shift from traditional cost-containment focused models.
The intersection of the IRA with the Enhancing Oncology Model (EOM) presents both challenges and opportunities for redefining value in cancer care, with stakeholders calling for approaches that better align with clinical realities and patient needs.
